Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes (original) (raw)

“…Metformin, a commonly prescribed drug for type 2 diabetes, increases lifespan and healthspan of male mice (Martin-Montalvo et al, 2013). However, emerging evidence from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial has challenged this conclusion and found that intensive glycemic control had neutral effects on death and nonfatal cardiovascular events among persons with advanced type 2 diabetes, and may paradoxically increase cardiovascular-related death (Accord_Study_Group, 2016; Accord_Study_Group et al, 2011). Recent studies suggest that calorie restriction also extends lifespan in a context-dependent manner, though it uniformly improves metabolic health (Mattison et al, 2012; Mitchell et al, 2016; Pearson et al, 2008).…”